Three distinct signals converged on SNPS Wednesday. An analyst upgrade, a sharp shift in options positioning, and a cost-to-borrow move arrived within 24 hours — each pointing in broadly the same direction.
BNP Paribas analyst Andrew DeGasperi upgraded Synopsys to Neutral from Underperform today, setting a $420 price target against a current price of $413. The move matters less for where BNP landed — Neutral is hardly a ringing endorsement — and more for what it signals: one of the last notable bears on the stock is stepping back.
The broader analyst community is considerably more constructive. Seventeen of 19 covering analysts rate the stock a Buy. The consensus mean target sits at $546, implying 32% upside from current levels. Wells Fargo raised its rating to Overweight on September 10. Morgan Stanley upgraded to Overweight on September 8. The direction of analyst travel has been clearly upward.
Earnings are due September 30. The most recent report, in late August, sent the stock up 13.7% in a single session.
The put-call ratio tells a consistent story. It sat at 0.92 on September 23, some 2.3 standard deviations below its 20-day mean of 1.13. The ratio has been dropping steadily. As recently as early September it was trading above 1.20 — a level associated with hedging demand. Now calls are comfortably outpacing puts.
The 52-week low on the PCR is 0.43, so there is room to run on the bullish side. But the velocity of the move is notable. The shift from above 1.20 to below 0.93 has happened in roughly three weeks, aligned with the sequence of analyst upgrades.
Cost to borrow rose 76% in one week to 0.48%. The direction is worth flagging. But the absolute level remains low — well under 1% — and availability is extremely loose at 6,882% (over 188 million shares available to borrow versus roughly 5.5 million currently shorted). The borrow market is not under any meaningful stress.
Short interest stands at 2.9% of free float and has drifted only modestly higher over the past month. This is not a heavily shorted stock, and the CTB move reflects a small nominal increase in borrow demand rather than a genuine squeeze dynamic.
Watch: Whether SNPS can close the gap toward the $546 consensus target heading into earnings — and whether the PCR compression holds or reverses on any pre-print volatility.
See the live data behind this article on ORTEX.
Open SNPS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
